Browse by Audience
Skip to content
Papers of the Week
Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
Abstract
Ileal bile acid transporter inhibition is a novel therapeutic concept for cholestatic pruritus and cholestatic liver disease progression. Odevixibat, a potent, selective, reversible ileal bile acid transporter inhibitor, decreases enteric bile acid reuptake with minimal systemic exposure. Oral odevixibat safety, tolerability, and efficacy in pediatric patients with cholestatic liver disease and pruritus were evaluated.